Elevance Health Inc. (ELV) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $419.21 (+0.40%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Ann Hynes | Mizuho Securities | $350.00 | -16.5% |
| Jan 29, 2026 | Jason Cassorla | Guggenheim | $396.00 | -5.5% |
| Jan 22, 2026 | Jason Cassorla | Guggenheim | $414.00 | -1.2% |
| Jan 9, 2026 | Ann Hynes | Mizuho Securities | $413.00 | -1.5% |
| Jan 8, 2026 | Justin Lake | Wolfe Research | $425.00 | +1.4% |
| Jan 5, 2026 | Andrew Mok | Barclays | $404.00 | -3.6% |
| Dec 19, 2025 | George Hill | Deutsche Bank | $320.00 | -23.7% |
| Oct 14, 2025 | Erin Wright | Morgan Stanley | $359.00 | -14.4% |
| Oct 7, 2025 | Stephen Baxter | Wells Fargo | $412.00 | -1.7% |
| Jun 9, 2025 | David MacDonald | Truist Financial | $500.00 | +19.3% |
| Oct 21, 2024 | David Windley | Jefferies | $529.00 | +26.2% |
| Oct 21, 2024 | Whit Mayo | Leerink Partners | $515.00 | +22.8% |
| Oct 18, 2024 | Sarah James | Raymond James | $485.00 | +15.7% |
| Oct 18, 2024 | Ben Hendrix | RBC Capital | $478.00 | +14.0% |
| Oct 18, 2024 | David MacDonald | Truist Financial | $520.00 | +24.0% |
| Oct 16, 2024 | Michael Ha | Robert W. Baird | $625.00 | +49.1% |
| Jul 18, 2024 | Ben Hendrix | RBC Capital | $585.00 | +39.5% |
| Jul 15, 2024 | David MacDonald | Truist Financial | $620.00 | +47.9% |
| Jun 24, 2024 | Erin Wright | Morgan Stanley | $643.00 | +53.4% |
| May 29, 2024 | Michael Ha | Robert W. Baird | $649.00 | +54.8% |
Top Analysts Covering ELV
ELV vs Sector & Market
| Metric | ELV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.21 | 2.25 | 2.42 |
| Analyst Count | 29 | 8 | 18 |
| Target Upside | +6.7% | +16187.2% | +19.5% |
| P/E Ratio | 17.77 | 3.77 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $186.70B | $193.62B | $197.51B | 14 |
| 2027-03-31 | $48.24B | $49.59B | $53.57B | 6 |
| 2027-06-30 | $48.24B | $49.59B | $53.57B | 6 |
| 2027-09-30 | $48.73B | $50.09B | $54.11B | 6 |
| 2027-12-31 | $48.23B | $49.58B | $53.56B | 6 |
| 2028-03-31 | $51.01B | $52.45B | $56.65B | 5 |
| 2028-06-30 | $50.51B | $51.93B | $56.09B | 5 |
| 2028-09-30 | $50.56B | $51.98B | $56.15B | 6 |
| 2028-12-31 | $50.37B | $51.78B | $55.94B | 8 |
| 2029-12-31 | $212.45B | $217.35B | $221.88B | 5 |
| 2030-12-31 | $224.33B | $229.50B | $234.28B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $26.27 | $26.53 | $28.08 | 15 |
| 2027-03-31 | $11.58 | $12.01 | $13.26 | 8 |
| 2027-06-30 | $6.82 | $7.07 | $7.81 | 8 |
| 2027-09-30 | $5.90 | $6.12 | $6.76 | 13 |
| 2027-12-31 | $4.01 | $4.15 | $4.59 | 8 |
| 2028-03-31 | $12.80 | $13.27 | $14.65 | 9 |
| 2028-06-30 | $7.61 | $7.89 | $8.71 | 12 |
| 2028-09-30 | $6.94 | $7.20 | $7.95 | 9 |
| 2028-12-31 | $5.61 | $5.82 | $6.42 | 9 |
| 2029-12-31 | $41.50 | $42.75 | $43.91 | 2 |
| 2030-12-31 | $44.78 | $46.13 | $47.38 | 2 |
Frequently Asked Questions
What is the analyst consensus for ELV?
The consensus among 29 analysts covering Elevance Health Inc. (ELV) is Buy with an average price target of $444.06.
What is the highest price target for ELV?
The highest price target for ELV is $649.00, set by Michael Ha at Robert W. Baird on 2024-05-29.
What is the lowest price target for ELV?
The lowest price target for ELV is $320.00, set by George Hill at Deutsche Bank on 2025-12-19.
How many analysts cover ELV?
29 analysts have issued ratings for Elevance Health Inc. in the past 12 months.
Is ELV a buy or sell right now?
Based on 29 analyst ratings, ELV has a consensus rating of Buy (2.21/5) with a +6.7% upside to the consensus target of $444.06.
What are the earnings estimates for ELV?
Analysts estimate ELV will report EPS of $26.53 for the period ending 2026-12-31, with revenue estimated at $193.62B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.